|

Comparative Self-collection for Cervical Cancer Screening Pivotal Study

RECRUITINGN/ASponsored by Mel Mont Medical
Actively Recruiting
PhaseN/A
SponsorMel Mont Medical
Started2026-07-09
Est. completion2026-08
Eligibility
Age25 Years – 65 Years
SexFEMALE
Healthy vol.Accepted
Locations11 sites

Summary

To evaluate whether individuals drawn from the intended use population can successfully interpret and follow the IFU for the Mia by XytoTest self-collection device and perform a vaginal sample collection yielding sufficient cellular material for primary hrHPV screening. To assess the clinical performance of Mia self-collected vaginal specimens by evaluating agreement with paired clinician-collected cervical specimens for the detection of high-risk HPV, when both specimen types are analyzed using the cobas HPV Test (Roche Molecular Systems). Residual samples may be used to determine adequacy for additional assays that require vaginal and/or cervical specimens (such as mRNA E6 and E7 Biomarker Test, dual stain cytology).

Eligibility

Age: 25 Years – 65 YearsSex: FEMALEHealthy volunteers accepted
Inclusion Criteria:

Group 1: General Population Group

1. Participants are 25 to 65 years of age and willing to provide informed consent.
2. Participants have an intact cervix.

Group 2: Enriched Population Group

1. Participants are 25 to 65 years of age and willing to provide informed consent.
2. Participants have an intact cervix.
3. One or more of: prior diagnosis of hrHPV within previous 6 months; abnormal cervical Pap cytology result of HSIL or higher (HSIL, AIS, or invasive carcinoma per the Bethesda 2014 system) within previous 6 months; and/or presenting for colposcopy/LEEP/excisional intervention.

Exclusion Criteria:

Apply to all groups:

1. Impaired decision-making capacity or inability to provide informed consent.
2. History of partial or total hysterectomy, including removal of the cervix.
3. Cervical tissue alteration or surgery within 5 months prior (conization, LEEP, laser ablation, or cryotherapy).
4. Current pregnancy (based on self-reporting).
5. Active menstruation at time of specimen collection.
6. Vaginal bleeding within 48 hours.
7. Have had sex or used tampons, creams, or other vaginal products in the last 48 hours.
8. Participation in another clinical study that, in the investigator's opinion, would interfere with the results of this study.
9. Any medical reason that, in the investigator's opinion, would disqualify the participant for a routine pelvic exam with cervical sample collection.

Conditions3

CancerHPVHPV - Anogenital Human Papilloma Virus Infection

Locations11 sites

ASR Arizona CGA
Reena Grewal208-906-1600reena@idahoasr.com
Integrated Clinical Research
Sherman Oaks, California, 91403
Iryna McCormick818-861-0088i.mccormick@icrsite.com
Altus Clinical Research
Lake Worth, Florida, 33461
Stephanie Feliz561-641-0404sfeliz@altusresearch.com
Zenacare Research
North Miami Beach, Florida, 33169
Paola Rothberg305-902-3135paola@zenacare.com
ASR Idaho CGI
Boise, Idaho, 83702
Stephanie Canning208-906-1600stephaniec@idahoasr.com

Find trials near these locations

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.